Special Issue

Next-Generation Envenoming Therapies: From Small Molecules to Antibodies

Message from the Guest Editors

Antivenom remains the gold-standard treatment for envenoming by snakes, scorpions, spiders and other venomous animals, yet remains largely unchanged since its first development in the 19th Century. Current antivenoms using animal-derived immunoglobulins are associated with numerous deficiencies as a result of this manufacturing practice, including poor efficacy, high manufacturing and treatment cost, high incidence of adverse reactions, and poor thermostability. Current strategies under investigation to improve the treatment of envenoming include the development of human/ised monoclonal antibodies (or cocktails thereof), rational immunogen design to enhance animal-derived antivenoms, and small molecule drugs, to name a few. The focus of this Special Issue of *Toxins* will be the development of next-generation envenoming therapies, spanning the breadth of current research from small molecules to immunoglobulins. We encourage original research and review articles that exemplify current research activities in next-generation treatments for envenoming by any venomous animal.

Guest Editors

Dr. Stefanie Menzies
Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK
Prof. Dr. Nicholas R. Casewell
Alistair Reid Venom Research Unit, Liverpool School of Tropical Medicine, Liverpool L3 5QA, UK

Deadline for manuscript submissions

closed (20 July 2023)

Toxins

an Open Access Journal by MDPI

Impact Factor 4.0
CiteScore 8.2
Indexed in PubMed

mdpi.com/si/150948

Toxins
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
toxins@mdpi.com

mdpi.com/journal/toxins

Toxins

an Open Access Journal by MDPI

Impact Factor 4.0
CiteScore 8.2
Indexed in PubMed

mdpi.com/journal/toxins

About the Journal

Message from the Editor-in-Chief

Toxinology is an incredibly diverse area of study, ranging from field surveys of environmental toxins to the study of toxin action at the molecular level. The editorial board and staff of *Toxins* are dedicated to providing a timely, peer-reviewed outlet for exciting, innovative primary research articles and concise, informative reviews from investigators in the myriad of disciplines contributing to our knowledge on toxins. We are committed to meeting the needs of the toxin research community by offering useful and timely reviews of all manuscripts submitted. Please consider *Toxins* when submitting your work for publication.

Editor-in-Chief

Prof. Dr. Jay Fox
Department of Microbiology, University of Virginia, Charlottesville, VA, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank:

JCR - Q1 (Toxicology) / CiteScore - Q1 (Toxicology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

MDPI